Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States

Manevy, Federico ; Filkauskas, Gabriele ; Levy, Pierre ; Fredriksson, Judy ; Sussell, Jesse

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.544-544 [Periódico revisado por pares]

Texto completo disponível